Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Recruiting in Palo Alto (17 mi)
+2 other locations
SH
Overseen byScott Haake, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Vanderbilt-Ingram Cancer Center
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
Research Team
SH
Scott Haake, MD
Principal Investigator
Vanderbilt Medical Center
Eligibility Criteria
Inclusion Criteria
Renal Cell Carcinoma with clear cell component
Stage IV
Receiving IO-containing regimen
See 1 more
Treatment Details
Interventions
- Blood collection (N/A)
- Urine collection (N/A)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: RCC with clear cell componentExperimental Treatment2 Interventions
Group II: Healthy Volunteer (no longer recruiting)Experimental Treatment2 Interventions
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Tennessee Valley Health Care SystemNashville, TN
The University of Texas MD Anderson Cancer CenterHouston, TX
Vanderbilt University Medical CenterNashville, TN
Loading ...
Who Is Running the Clinical Trial?
Vanderbilt-Ingram Cancer Center
Lead Sponsor
Trials
221
Patients Recruited
64,400+
United States Department of Defense
Collaborator
Trials
940
Patients Recruited
339,000+